Heron Bay Capital Management Has $6.33 Million Stock Holdings in Zoetis Inc. $ZTS

Heron Bay Capital Management raised its stake in Zoetis Inc. (NYSE:ZTS) by 36.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 43,224 shares of the company’s stock after purchasing an additional 11,490 shares during the period. Zoetis accounts for approximately 1.2% of Heron Bay Capital Management’s investment portfolio, making the stock its 28th biggest position. Heron Bay Capital Management’s holdings in Zoetis were worth $6,325,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZTS. CIBC Asset Management Inc lifted its holdings in Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after purchasing an additional 10,434 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp grew its holdings in Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares in the last quarter. Ninety One UK Ltd increased its position in Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after buying an additional 183,686 shares during the period. Quilter Plc lifted its holdings in shares of Zoetis by 10.2% during the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after buying an additional 40,615 shares in the last quarter. Finally, Swedbank AB boosted its position in shares of Zoetis by 60.4% in the third quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after acquiring an additional 917,598 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $122.06 on Friday. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The company has a market cap of $51.53 billion, a PE ratio of 20.28, a price-to-earnings-growth ratio of 1.92 and a beta of 0.95. The company has a 50 day moving average of $126.16 and a 200-day moving average of $133.42. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion during the quarter, compared to the consensus estimate of $2.36 billion. During the same period in the prior year, the business earned $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZTS. HSBC set a $140.00 price objective on shares of Zoetis in a research note on Wednesday, December 10th. Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, January 28th. KeyCorp started coverage on Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. The Goldman Sachs Group upgraded Zoetis to a “buy” rating in a research note on Monday, December 15th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.